CA-NETAPP
26.6.2024 14:01:30 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that NetApp ONTAP® Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI) has received a AAA rating from SE Labs, an independently-owned and run testing company that assesses security products and services. SE Labs validated the protection effectiveness of NetApp ARP/AI with 99 percent recall—a metric that measures malware detection rates—for ransomware attacks, while noting the absence of false positives.
When responding to ransomware attacks, seconds can make the difference between ensuring continuity and a massive business disruption. Organizations need fast, automated, and accurate detection and response capabilities built into their primary storage systems to minimize the damage done by lost production data and downtime. NetApp ARP/AI, with its AI-powered ransomware detection capability, addresses this gap by providing real-time detection and response to minimize the impact of cybersecurity threats.
SE Labs rigorously tested NetApp ARP/AI against hundreds of known ransomware variants with impressive results. NetApp ARP/AI demonstrated 99 percent detection of advanced ransomware attacks. NetApp ARP/AI also achieved 100 percent detection of legitimate files without flagging any false positives, indicating a strong ability to operate in a business context without contributing to alert fatigue.
Ensuring data is secure against internal and external threats is a critical part of making data infrastructure intelligent which then empowers customers to turn disruption into opportunity. This validation of NetApp’s AI-powered ransomware detection capabilities underscores how NetApp is staying at the forefront of AI innovation by both enabling AI adoption and applying AI to data services. NetApp’s newly released more powerful, all-flash storage systems help enterprises leverage their data to drive AI workloads, built on NetApp’s secure storage infrastructure.
"NetApp has passed a significant milestone in the fight against ransomware as the first and only storage vendor to offer AI-driven on-box ransomware detection with externally validated top-notch protection effectiveness,” said Dr. Arun Gururajan, Vice President, Research & Data Science at NetApp. “Ransomware detection methodologies that rely only on backup data are too slow to effectively mitigate the risks businesses face from cybersecurity threats. NetApp ARP/AI hardens enterprise storage by providing robust, built-in detection capabilities that can respond to ransomware threats in real time. The AAA rating we achieved from SE Labs is the result of our commitment to innovation in intelligent data infrastructure and our drive to find new ways to make NetApp the most secure storage on the planet.”
By embedding ransomware detection in storage, NetApp ARP/AI helps customers improve their cyber resilience while reducing the operational burden and skills required to maintain their intelligent data infrastructure. NetApp ARP/AI’s detection technology continuously adapts and evolves as new ransomware variants are discovered. This continuous retraining on the latest ransomware strains ensures that NetApp ARP/AI remains at the forefront of protection effectiveness, offering organizations a future-proof defense against the dynamic ransomware landscape.
To see the full results of the tests, read the SE Labs Report.
NetApp ARP/AI is currently in tech preview. Customers can request to participate in the tech preview by reaching out to their NetApp sales representative.
Additional Resources
- NetApp, the First and Leading AI-Powered Autonomous Ransomware Protection Native to Storage Achieves Remarkable AAA Rating and 99% Detection Accuracy and 100% Legitimate Accuracy in SE Labs Validation Testing
- Protect, Detect, Recover; Guaranteed
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626446291/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
